Research on Aneurysm Growth Prediction in Vascular Dilation Caused by Bicuspid Aortic Valve Based on VDM and CFD
Key facts
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 1,000 people enrolled
- Started
- 1 Jan 2020
- Ended
- 1 Feb 2026
- Type of study
- Observational
- Treatments tested
- Transcatheter Aortic Valve Replacement
- Record updated
- 24 August 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- Patients are eligible for inclusion if they are male or non-pregnant female aged 18 to 85 years, diagnosed with Bicuspid Aortic Valve (BAV) by CTA, and have successfully undergone Transcatheter Aortic Valve Replacement (TAVR) with available pre-operative, post-operative (1-3 months), and follow-up (6-12 months) CTA imaging. The CTA scan range must cover cranially at least the origin of the brachiocephalic trunk, left common carotid artery, and left subclavian artery, and caudally at least the origin of the internal and external iliac arteries
Who cannot take part
- Patients are excluded if they have traumatic or iatrogenic aortic dissection, isolated aortic aneurysm without BAV, connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, or prior cardiac or aortic surgery including surgical aortic valve replacement or aortic repair. Additional exclusions include insufficient number of CTA scans or inadequate scan range, poor CTA image quality due to motion artifacts or inadequate contrast enhancement precluding accurate segmentation, or image registration failure precluding completion of VDM analysis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Bicuspid aortic valve (BAV) is the most common congenital valvular malformation, characterized by heterogeneous phenotypic subtypes that predispose patients to secondary aortic pathologies, including valvular dysfunction and ascending aortic dilation. With approximately 50% of BAV patients developing aortic dilation, a prevalence that continues to rise, accurate assessment of postoperative aortic remodeling remains a critical unmet clinical need for early risk stratification and optimized therapeutic decision-making. Currently, clinical surveillance relies heavily on periodic manual measurement of the maximum aortic diameter on follow-up computed tomography angiography (CTA), yet this approach suffers from several inherent limitations. It is a lagging indicator that detects irreversible wall damage only after significant enlargement has occurred. It oversimplifies complex three-dimensional morphological changes into a single linear dimension. It exhibits substantial intra- and inter-observer variability. It is also inefficient for large-scale longitudinal data management. Although alternative metrics such as computational fluid dynamics (CFD) derived hemodynamic parameters and morphological geometric features have been explored, existing methods remain constrained by static single-time-point analyses that fail to capture the dynamic biomechanical evolution driving aneurysm progression, high technical barriers that preclude routine clinical integration, and a lack of comprehensive models that systematically integrate dynamic deformation, static anatomy, and hemodynamic information. To address these gaps, this study aims to develop a fully automated, quantitative, and dynamic risk prediction system that leverages vascular deformation mapping (VDM) for noninvasive early detection of regional aortic deformation, integrates multiparameter features including dynamic deformational, static anatomical, and hemodynamic characteristics through an artificial intelligence model, and delivers intuitive structured reports to directly support clinical decision-making, thereby enabling earlier intervention and improved patient outcomes.
The group in the trial
- BAV with Aortic Dilation Cohort
Bicuspid Aortic Valve (BAV) patients aged 18-85 years who have successfully undergone Transcatheter Aortic Valve Replacement (TAVR) and have available pre-operative, post-operative, and follow-up CTA imaging with scan coverage from supra-aortic branches to iliac arteries. Patients with connective tissue disorders (e.g., Marfan syndrome), prior cardiac/aortic surgery, traumatic or iatrogenic dissection, or insufficient imaging quality will be excluded. All enrolled patients will be retrospectively analyzed as a single observational cohort to develop and validate an AI-based risk prediction model for aortic dilation. No intervention or randomization is applied.
Treatment: Transcatheter Aortic Valve Replacement
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 24 August 2026